ISSN: 1734-1922
Archives of Medical Science Special Issues
Current issue Archive Archives of Medical Science
1/2010
 
Share:
Share:
more
 
 
abstract:

Risk factor modification after ACS
Benefits of lipid regulation in acute coronary syndrome

Chris J. Packard

Arch Med Sci 2010; 6, 1A: S 76–S 82
Online publish date: 2010/01/26
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Lipid lowering therapy with statins has proven beneficial in patients with acute coronary syndrome (ACS). Outcome trials have demonstrated that the high risk of a recurrent coronary event or stroke can be reduced by about 15% using these agents. Further, greater benefit appears to be present when more aggressive treatment regimens (higher statin doses) are followed. Lipoprotein levels measured in the days following an ACS episode may not be a good guide to therapy due the effects of the acute phase response. Other lipid regulating modalities including HDL raising drugs are being explored. Theoretically, these approaches could be beneficial not only in facilitating reverse cholesterol transport but also in altering inflammatory and oxidative pathways. Their utility needs to be tested rigorously in clinical trials.
keywords:

cholesterol, statins, lipoprotein, trials

Quick links
© 2020 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe